The case for & against
Bull & Bear analysis
Bearish
23andMe, Inc. (NASDAQ: ME) is a pioneer in the personal genomics and biotechnology sector, focusing on genetic testing, health insights, and therapeutics development. The company is transitioning its business model to emphasize high-value consumer membership services—including telehealth and preventive health solutions—while leveraging its extensive genetic data for collaborative research and therapeutic innovations. As it pivots away from direct therapeutic development, 23andMe is keenly positioned to capitalize on trends towards integrated health management.
Bull says
- ↑Subscription revenue grew 41% YoY to $20M in Q1 2025, boosting recurring cash flow
- ↑Operating expenses fell 17% YoY to $84M, narrowing net loss to $59M
- ↑Membership base surpassed 15M, driving cross-sell and telehealth expansion
- ↑AI-driven health insights platform under development to deepen customer engagement
- ↑GSK data licence revenue expected beginning H2 FY25, diversifying income
- ↑High earnings yield and strong profitability metrics suggest improving sentiment
Bear says
- ↓Total revenue fell 34% YoY to $40M in Q1 2025, net loss $69M
- ↓Cash position declined to $127M, requiring fresh funding
- ↓Data breach remediation cost $2.7M, risking customer trust
- ↓Conclusion of GSK exclusive term reduces near-term licensing revenue
- ↓40% workforce reduction may disrupt innovation and execution
- ↓Negative growth metrics, high short interest, and volatile stock price raise caution
Earnings Call · Q2 2024 · Mgmt. Guidance
Updated 09-10-2026neutral
Transcript signals
Bull points
- We are moving toward a more subscription-based longitudinal model so we can have a positive impact and help our customers take action to improve their health over time.
- The subscription business also offers a much more sustainable and attractive operating model for us to create value for our customers and investors.
- Yesterday, we launched a new subscription membership called Total Health, a continued effort to be the world's best at risk prediction.
Bear points
- The year-over-year decrease in revenue was primarily due to the conclusion of our exclusive discovery July, providing one month of collaboration revenue in the quarter compared to a full three months in the prior year.
- net loss for the quarter was 75 million compared to net loss for the same period in the prior year of 66 million.
- Within the therapeutics business, we continue to invest in programs we believe are most strategically and financially valuable. With the end of the exclusive discovery term under the GSK collaboration in July, we decided to narrow our discovery and development efforts to areas that best align with our core strength.
Read full transcript analysis ›